Retatrutide and Semaglutide Together: What Researchers Have Found

What the phase 2 retatrutide data actually showed, and why it drew comparisons with semaglutide

The interest in pairing retatrutide with semaglutide largely traces back to a single phase 2 trial published in the New England Journal of Medicine in 2023. In that study, adults with obesity who received the highest retatrutide dose (12mg, once weekly) lost around 24% of their body weight over 48 weeks. That figure caught attention because it exceeded, in a shorter timeframe, the roughly 15% average loss seen with semaglutide 2.4mg in the 68-week STEP 1 trial. The mechanistic reason is straightforward: retatrutide acts on three receptors (GIP, GLP-1 and glucagon), whereas semaglutide acts on one (GLP-1), and if you want a thorough breakdown of how the two medicines compare, our page on whether retatrutide is the same as semaglutide walks through the key differences in detail. The glucagon component in particular appears to drive additional energy expenditure on top of the appetite suppression shared by both medicines.

That comparison fuelled a logical but medically premature conclusion, if semaglutide works and retatrutide works better, could combining them accelerate results further? The trial data does not support that leap. The phase 2 study was designed to test retatrutide alone, not alongside other agents. Phase 3 trials are ongoing, and none, to date, includes a semaglutide co-administration arm. Until that evidence exists, no prescriber can responsibly offer the combination.

Why combining GLP-1 pathway medicines is not simply additive

Both retatrutide and semaglutide bind to the GLP-1 receptor. Adding a second GLP-1 agonist on top of an existing one does not double the signal, the receptor is already substantially occupied. The likely result is an amplified side-effect burden (nausea, vomiting, diarrhoea and the more serious risks of pancreatitis and dehydration) without a proportionate gain in efficacy, and our dedicated page on stacking semaglutide and retatrutide covers exactly why the evidence does not support this approach. The NHS patient information for semaglutide lists these gastrointestinal effects as the most common reason people reduce or stop treatment; layering a second agent targeting the same receptor would heighten rather than bypass that problem.

The glucagon receptor component in retatrutide adds complexity too. Glucagon raises blood glucose; medicines that suppress it can affect blood sugar in ways that interact with other treatments. Anyone considering what the clinical picture might look like when retatrutide eventually reaches market can read about what a switch from semaglutide to retatrutide might involve. That page explores the transition pathway, and the emerging view among researchers is that clinicians will manage a switch, not a combination.

If you are currently on Wegovy and wondering whether a stronger option is coming, that instinct is well-founded. The question is one of timing and licensing, not of adding medicines to your current plan.

Where semaglutide stands right now for people who want the best-evidenced licensed option

Semaglutide remains one of two medicines licensed in the UK for weight management by injection, the other being tirzepatide (Mounjaro). Both carry full MHRA authorisation and a body of published trial evidence large enough for NICE to have assessed them formally. In June 2026 the MHRA also approved an oral semaglutide tablet (Wegovy tablets) (the first oral GLP-1 medicine licensed for weight management in the UK) giving people who prefer not to inject a licensed alternative.

For people weighing up which licensed option suits them best, a practical starting point is spending sixty seconds on the NHS BMI calculator to confirm you fall within the licensed eligibility range before a consultation. That one check focuses the conversation and avoids a wasted appointment. The cost side of semaglutide treatment (which varies by dose and provider) is covered separately on our Wegovy cost page.

Retatrutide may well reach a UK prescriber's desk in the next few years. When it does, the clinical pathway will almost certainly involve stopping an existing GLP-1 medicine before starting it, not running both in parallel. The semaglutide to retatrutide transition is already a question our team fields regularly, and the honest answer is: watch the phase 3 data, keep your current treatment optimised, and revisit the conversation when a licence exists.

What to do if you are currently on semaglutide and feel your results have plateaued

Plateaus on semaglutide are real and documented. They are not a sign that the medicine has stopped working entirely (appetite suppression continues even when the scale stops moving) but they do warrant a clinical conversation. A prescriber will look at whether you are on the highest tolerated dose, how your diet and activity patterns sit alongside treatment, and whether any medical factors are contributing. Switching to a different mechanism (tirzepatide's dual GIP and GLP-1 action, for instance) is an evidence-based option that is available today through a regulated UK pharmacy with a valid prescription.

Chasing unlicensed combinations, or sourcing retatrutide through unregulated channels, is not. The MHRA has warned repeatedly about counterfeit and unlicensed weight-loss products sold online; a medicine still in phase 3 trials is, by definition, not legally obtainable on prescription in the UK. Our semaglutide overview covers what is currently licensed and how clinical review works, and the team at our clinical team page can give you a sense of the prescriber-led approach we take to these conversations. If you are ready to explore your options with a licensed treatment today, checking your eligibility is a good place to start.

Check your eligibility with a free consultation from our prescribers.